An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19

Creative Commons License

Karatas H., Hanashalshahaby E. H. A., Catal U., Butun Y. E., Kurt E., Gursel S., ...Daha Fazla

Chemical Papers, cilt.77, sa.3, ss.1695-1702, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 3
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s11696-022-02595-1
  • Dergi Adı: Chemical Papers
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core
  • Sayfa Sayıları: ss.1695-1702
  • Anahtar Kelimeler: Favipiravir synthesis, 3,6-Dichloropyrazine-2-carbonitrile, Covid-19 treatment, Process development, Active Pharmaceutical Ingredient (API) synthesis
  • İstanbul Medipol Üniversitesi Adresli: Evet

Özet

Favipiravir is a wide-spectrum antiviral generic drug that has received large attention during the recent COVID-19 pandemic. While there are synthetic strategies for favipiravir synthesis, economical procedures could contribute to industrial scale synthesis and availability. Accordingly, our efforts focused on an economic and scalable procedure for favipiravir synthesis via the 3,6-dichloropyrazine-2-carbonitrile intermediate obtained from 3-aminopyrazine-2-carboxylic acid. The process afforded favipiravir with 43% yield (from 3,6-dichloropyrazine-2-carbonitrile, by fluorination, hydroxylation, and nitrile hydrolysis reactions) and greater than 99% purity without a chromatographic purification step. Graphical abstract: [Figure not available: see fulltext.]